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ABSTRACT
Introduction: Biologic therapies are efficacious
but costly. A number of health economic
models have been developed to determine the
most cost-effective way of using them in the
treatment pathway. These models have
produced conflicting results, driven by
differences in assumptions, model structure,
and data, which undermine the credibility of
funding decisions based on modeling studies.
A Consensus Working Party met to discuss
recommendations and approaches for future
models of biologic therapies.
Methods: Our working party consisted of
clinical specialists, modelers, and policy
makers. Two 1-day meetings were held for
members to arrive at consensus positions on
model structure, assumptions, and appropriate
data sources. These views were guided by
clinical aspects of rheumatoid and psoriatic
arthritis and the principles of evidence-based
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medicine. Where opinions differed, we sought
to identify a research agenda that would
generate the evidence needed to reach
consensus.
Results: We gained consensus in four areas of
model development: initial response to
treatment; long-term disease progression;
lifetime costs and benefits; and model
structure. Consensus was also achieved on
some key parameters such as choices of
outcome measures, methods for extrapolation
beyond trial data, and treatment switching. A
research agenda to support further consensus
was also identified.
Conclusion: Consensus guidance that fully
reflects current evidence and clinical
understanding was gained successfully. In
addition, research needs have been identified.
Such guidance can be updated as evidence
develops and policy questions change and
need not be prescriptive as long as deviations
from consensus are clearly explained and
justified.
Funding: Arthritis Research UK and the UK
Medical Research Council Network of Hubs for
Trials Methodology Research.
Keywords: Arthritis; Biologics; Economic
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INTRODUCTION
Biologic therapies represent a recent addition to
treatments for inflammatory joint diseases such
as rheumatoid arthritis (RA) and psoriatic
arthritis (PsA). While their efficacy has been
established in a number of clinical trials and
cost-effectiveness demonstrated in a number of
assessments [1, 2], the evidence base is still
associated with substantial uncertainty, and
this poses a considerable challenge for
decision-making in defining the role of
different agents in the sequence of
disease-modifying drugs used to manage these
chronic diseases. A workshop to explore these
challenges took place in 2010, the proceedings
of which were disseminated in a series of papers
[3–10]. A key finding of the workshop was that,
despite the importance of economic models in
guiding policy on the adoption of biologic
therapies, there was no clear consensus on
how the models should be structured, how
they should be informed from data, or even
which data were the most appropriate.
Moreover, the differences between the models
were sufficiently substantial to lead to
contradictory recommendations. If consensus
views were available beforehand on the
desirable properties of the economic model,
and the data sources that should inform it, this
would assist model development and review to
inform future policy decisions. With this in
mind, a Consensus Working Party on decision
models for biologic therapies in RA and PsA was
formed to identify the current scope for
consensus, and identify gaps in the evidence
base where further research is needed to support
future consensus.
METHODS
The working party was set up to bring together
key expertise as comprehensively as possible.
Attendees included leading clinical experts,
health economists involved in the
development of the main existing
cost-effectiveness models that have informed
policy making in the UK, and key individuals
from Health Technology Assessment
organizations and significant funders of
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research (Table 1). Their remit was to: (1) frame
and clarify the issues for which consensus needs
to be sought; (2) set out, where possible, initial
recommendations for consensus approaches for
models, based on sound methodology, clinical
judgment, and decision-maker preferences; and
Table 1 Members of the Consensus Working Party
Participant Organization Relevant expertise and experience
Professor A.
E. Ades
(chair)
School of Social and Community Medicine,
University of Bristol
Evidence synthesis methodology, member of NICE
appraisals committee since 2003
Dr. Paresh
Jobanputra
Queen Elizabeth Hospital, Queen Elizabeth
Medical Centre, Birmingham
Clinical specialist, co-author of multiple NICE
technology appraisals of biologic therapies
Professor
Ernest Choy
Cardiff University School of Medicine Clinical specialist, expert advisor to NICE, member
of EULAR
Dr. Philip
Helliwell
Chapel Allerton Hospital, Leeds and St Luke’s
hospital, Bradford
Clinical specialist, expert advisor to evaluation group
for NICE PsA guidance, member of GRAPPA
Professor
Andrew
Stevens
Department of Primary Care, Public and
Occupational Health, University of Birmingham
Health technology assessment, chair of a NICE
appraisal committee since 2005
Professor Ken
Stein
PENTAG, University of Exeter Medical School Health technology assessment, vice chair of NICE
appraisal committee, director of PENTAG,
representative of the UK HTA program
Dr. Suzanne
Verstappen
ARUK Epidemiology Unit, University of
Manchester
Arthritis epidemiology, member of NOAR staff
Dr. Pelham
Barton
School of Health and Population Sciences,
University of Birmingham
Health economic modeling, developer of the BRAM
Dr. Allan
Wailoo
School of Health and Related Research, University
of Shefﬁeld
Health economics/modeling, director of the NICE
DSU, co-developer of the Shefﬁeld RA model
Mr. Jon Tosh School of Health and Related Research, University
of Shefﬁeld
Health economics/modeling, member of the NICE
DSU and ScHARR-TAG, co-developer of the
Shefﬁeld RA model
Dr. Laura
Bojke
Centre for Health Economics, University of York Health economics/modeling, co-developer of the
York PsA model
Dr. Jason
Madan
School of Social and Community Medicine,
University of Bristol and Warwick Medical
School
Health economics/modeling, evidence synthesis
BRAM Birmingham Rheumatoid Arthritis Model, DSU Decision Support Unit, EULAR European League Against
Rheumatism, GRAPPA Group for Research and Assessment of Psoriasis and Psoriatic Arthritis, NICE National Institute
for Health and Care Excellence, NOAR Norfolk Arthritis Register, PENTAG Peninsular Technology Assessment Group,
PsA Psoriatic arthritis, RA Rheumatoid arthritis, ScHARR-TAG School of Health and Related Research Technology
Assessment Group
Rheumatol Ther (2015) 2:113–125 115
(3) set out an agenda for the research needed to
achieve consensus where existing evidence is
inconclusive. Four main topic areas for
consensus were identified, with specific issues
to address for each area (Table 2). Further details
of these issues, and their representation in
existing models, are presented elsewhere [8].
Two 1-day working party meetings were held
at the University of Birmingham in November
2011 and March 2012. Position papers
describing each of the issues above were
circulated prior to each meeting, with
members given time to provide feedback and
suggest additional considerations. These papers
defined the agenda for each meeting, where
consensus among participants was sought for
each aspect, guided by an understanding of the
clinical aspects of RA and PsA, and the
principles of evidence-based medicine, as set
out in documents such as the Cochrane
handbook [11] and the UK National Institute
for Health and Care Excellence (NICE) methods
guide for technology appraisals [12].
Where divergent opinions remained,
participants were asked to identify research
programs whose results would lead to greater
clarity and consensus in these areas. We present
below, for each model aspect listed above, a
summary of the consensus recommendations,
the outcome of discussions held on this topic at
the workshops, and recommendations for
further research to enhance future consensus.
A more detailed report of the background,
process and outcomes for the consensus
working party is available in online
supplementary material. The report was
reviewed by a separate independent panel of
clinical experts, and their commentary is also
available online.
This article is based on the discussions of the
Consensus Working Party and does not involve
any new studies of human or animal subjects
performed by any of the authors.
Table 2 Overview of topics and issues for consensus
Topic 1: modeling the initial response to treatment,
including:
Choice of scale to measure initial response
Link between response level and decision to continue
treatment
Choice and use of evidence to estimate effect of
treatment on initial response
Estimating the baseline response in the comparator
treatment
Modeling adverse events in the initial treatment phase
Inﬂuence of effect modiﬁers on treatment effects
Topic 2: longer-term disease progression in those who
continue treatment, including:
Choice of scale to measure long-term disease
progression
Rate of disease progression during long-term treatment
Treatment duration (i.e., time to withdrawal of
treatment due to lack of efﬁcacy and/or adverse
events)
Modeling adverse events in the long-term treatment
phase
The inﬂuence of effect modiﬁers on treatment
duration and disease progression
Topic 3: estimating lifetime costs and beneﬁts of
treatments, including:
Resource use implications to include in calculations
Modeling the relationship between disease severity and
mortality risk
Topic 4: structural modeling approaches:
Representing sequences of treatments
Cohort vs. individual patient models
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RESULTS
Modeling the Initial Response
to Treatment
Summary of Consensus View
• Disease Activity Score 28 (DAS28) should be
used to represent initial response to
treatment in RA.
• Models should reflect current guidelines and
withdraw treatment from patients with an
inadequate response. The timing of this
should follow current clinical guidelines, to
aid comparison of results among models,
although the impact of alternative stopping
rules can be explored in sensitivity analysis.
• Currently, robust evidence for effect
modification has not been identified, and
effect modification should not be included
in evidence synthesis of initial response
treatment effects.
• Models should represent the cause for
discontinuation of treatment (i.e., lack of
response or adverse events).
• Estimates of short-term response to biologics
should be based on all relevant trials and
derived using formal evidence synthesis
methodology that respects randomization.
Mapping functions should be used within
the synthesis so that trials can be included
even if they do not report DAS28.
• Mapping functions should also be used to
relate changes in DAS28 to changes in the
measure used to represent long-term disease
progression.
• Response rates to the non-biologic
comparator can be based on pooling
control arms from biologic trials, although
the comparability of trial and decision
populations should be considered.
• For PsA, PsA Response Criteria (PsARC) and
Psoriasis Area Severity Index (PASI) should
be used as outcome measures, although
disease-specific measures currently in
development may be used once they have
been validated.
Outcome of Workshop Discussions
Modeling the Initial Treatment
Phase Stopping rules do not fully reflect the
complexity of clinical decision-making at a
patient level. However, their use within
models is required to synthesize trial evidence,
link short-term and long-term outcomes, and
explore the cost-effectiveness implications of
different guidance. Therefore, models should
include such stopping rules, as long as it is
recognized that they do not fully specify
outcomes at a patient level. Currently, for RA,
the most appropriate measure to base such
stopping rules on is DAS28, because:
• DAS28 most closely reflects clinical benefit
of treatment in the short term.
• Relatively small changes are still clinically
meaningful to patients.
• It is an absolute scale (although the related
European League Against Rheumatism
[EULAR] response categories depend on
both absolute change in DAS and DAS at
endpoint).
• It is particularly appropriate for the UK,
where it has received support from clinical
experts in previous NICE appraisals, and is
the basis of current NICE guidance.
American College of Rheumatology (ACR)
20/50/70 was considered problematic because it
is a relative measure. However, given that it is
commonly reported there is a clear need for
mapping functions to characterize the
relationship between the two measures, as it is
not appropriate to exclude relevant studies
solely because they do not report DAS28. For
PsA, both outcomes (skin and joint symptoms)
need to be considered when modeling the
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initial treatment phase. PsA is a heterogeneous
condition, and there are types of PsA where
DAS28 could be the most appropriate measure
of response for joint symptoms. However,
disease-specific measures for PsA are in
development, so efforts to shift from PsARC
are unlikely to be worthwhile.
Effect Modification A number of factors are
potential modifiers for relative effects of
treatment on responder status. Mechanisms
for effect modification include ‘treatment
resistance’ (failure to respond to previous
drugs may indicate a lesser chance of
responding to the current drug) and
‘accumulated damage’ (disease duration is
associated with joint damage). Effect
modification may be more influential with
ACR 20/50/70 response, as this is a relative
response measure, sensitive to baseline disease
activity, than with DAS28, which is an absolute
measure.
Choice and Use of Evidence to Estimate Effect
of Treatment on Initial Response When
performing a synthesis of evidence to inform
modeled treatment effects, trials in
biologic-naive patients should be analyzed
separately from trials in patients with prior
biologic exposure, as should trials in biologics
with or without concomitant disease-modifying
antirheumatic drugs (DMARDs). Formal models
for effect modification could be derived from
individual patient data (IPD) sourced from
trials, or from observational data. A concern
with the latter is potential selection bias. Where
data is weak, expert elicitation could guide
adjustments related to changes in position
within the sequence. However, in the absence
of convincing evidence for effect modification,
the simpler approach of using unadjusted
treatment effects is preferable, particularly if
an absolute scale such as DAS28 is used for
response.
Estimating the Baseline Response in the
Comparator Treatment For modeling
purposes, relative treatment effects need to be
applied to the absolute proportion of (DAS28)
responders that would be seen if a conventional
DMARD was given instead of a biologic at the
relevant point in the sequence. The absolute
rate from the control arm of a biologic trial has
often been used for this purpose, as have
absolute rates from trials of conventional
DMARDs. An alternative would be to use
registry data. The latter would match the
required patient profile most closely, but
would be vulnerable to issues such as selection
bias. Therefore, the approach of pooling control
arms from trials with populations similar to the
decision population was preferred.
Modeling Adverse Events in the Initial
Treatment Phase The reason for not
continuing treatment past the initial phase
may have consequence for the choice and
efficacy of subsequent treatments, and may
also have cost implications. Models should
therefore distinguish between adverse events
and lack of efficacy as reasons for short-term
treatment termination. Information on adverse
event rates for different biologics will be
reported by most trials. Models should not
exclude trials that do not report causes for
treatment discontinuation. This can be avoided
by estimating the overall discontinuation rate
and the split between causes, rather than
estimating the absolute rate for each cause.
Current Available Evidence and Further
Research Needs
Mapping Between (Change in) DAS28 and ACR
20/50/70 While DAS28 is the preferred
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measure of short-term response to treatment for
the RA consensus model, many trials report
ACR 20/50/70 instead. Research is required to
develop mappings between ACR 20/50/70 and
DAS28, so that DAS28-based models are
informed by all relevant trials. Few, if any,
data sources collect or report both measures.
Therefore, mappings will need to be constructed
through indirect comparison with other
outcome measures sensitive to disease activity.
Since ACR measures are relative, while DAS28 is
an absolute scale, mappings should allow for
dependence on baseline disease activity. IPD
from trials would be the ideal evidence for this,
potentially supplemented by registry data (e.g.,
estimation of the DAS28/Health Assessment
Questionnaire [HAQ] change relationship from
the British Society for Rheumatology Biologics
Register [BSRBR]).
Mapping Between Existing PsA Outcome
Measures (PsARC, PASI) and Composite
Measures Currently in Development The
evaluation group for the UK NICE appraisal
of biologics for PsA developed a Bayesian
network meta-analysis to synthesize trial
evidence on short-term response to biologics
[13]. Treatment effects were estimated on four
outcomes: Psoriatic Arthritis Response Criteria
(PsARC), Arthritis Response Criteria (ARC;
both for joint symptoms), Psoriasis Area and
Severity Index (PASI; for skin symptoms), and
HAQ (for functional impact). The version
informing the economic model involved a
positive correlation between PsARC and PASI
response. The analysis, once updated and
extended to include newer treatments,
satisfies the requirements of the workshop
consensus and should inform future PsA
models that are based on PsARC and PASI
response. The Group for Research and
Assessment of Psoriasis and Psoriatic Arthritis
(GRAPPA) is an international organization
actively engaged in the development of
response measures in PsA [14]. The GRAppa
Composite Exercise (GRACE) study has
collected data on multiple PsA dimensions
and has recently developed novel composite
responder indices [15]. If clinical practice
changes as a result of these developments,
further research will be required to develop
mapping functions between new and existing
response measures.
Updating Reviews of Short-Term Adverse
Events The consensus model requires
estimation of the proportional split between
lack of efficacy and adverse events for those who
discontinue treatment at an early stage, based
on comprehensive and up-to-date evidence.
Systematic reviews of biologic trials
undertaken to inform UK NICE technology
appraisals can be used to identify this evidence
base. There are additional reviews of adverse
events in the literature [16]. Systematic reviews
of sequential biologic therapy have also assessed
the impact on the efficacy of a second biologic
of having experiences adverse events on the first
biologic [17]. This evidence base needs to be
collated, updated and synthesized to inform the
consensus model.
Modeling the Long-Term Treatment Phase
Summary of Consensus View
• HAQ should be used to represent disease
progression, although a multidimensional
measure which includes pain should be
considered for mapping disease progression
to health utilities.
• The source for mappings used between
outcome measures should be clearly stated
and justified, and be consistent with current
applied and methodological research.
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• Survival models may be used to extrapolate
beyond the follow-up period of data on the
duration of successful long-term treatment.
All relevant data should be used to fit such
models; this may include open-label trial
follow-up and registry data. However,
treatment duration differences between
biologics should not be assumed based on
observational data alone.
• Assumed rates of HAQ progression should be
consistent with observations from
longitudinal data.
• Models should distinguish between adverse
events and loss of efficacy as reasons for
treatment withdrawal.
• The rebound in disease progression on
treatment withdrawal should be
evidence-based as far as possible. Where
multiple scenarios are consistent with the
available evidence, the impact of alternative
plausible assumptions should be explored
through sensitivity analysis.
Outcome of Workshop Discussions
HAQ has been widely used in models to
represent disease progression, for historical
reasons. Several mapping algorithms between
HAQ and quality of life (QoL) measures (e.g.,
EQ5D) have been developed and used in
existing models [18, 19]. However, algorithms
for mapping between outcome measures such as
HAQ and EQ5D are an area of active research
[20], and the most appropriate algorithm for use
in decision models may change over time. For
example, recent research has suggested that
pain has an important influence on QoL in
patients with RA, independent of HAQ [24].
Therefore, models could in future use a
multidimensional (HAQ and pain) outcome
measure for disease progression.
Observational data have been used to
estimate the duration of treatment and the
rate of change in HAQ over time while on
treatment, and sometimes support assumed
differences between biologics. Models should
not be ‘hard-wired’ to exclude such differences,
but the reference case should only allow
differences between drugs of the same class if
based on data from randomized studies. The
impact of differences inferred from
observational data could be explored in
supplementary analyses, but estimates should
reflect the increased risk of bias. The estimates
may be more credible if based on observational
data collected in a clearly relevant population,
or on a synthesis of multiple sources of
non-randomized evidence.
HAQ progression is sometimes assumed to be
zero on biologics. This is not biologically
credible in the long term in view of the effect
of ageing on HAQ. Further long-term data are
needed in RA and PsA populations in remission.
Current models for non-biologics assume linear
progression at a rate which appears to result in
too many people reaching the HAQ ceiling too
quickly. Registries may give some data on HAQ
progression, and elicitation could also be used
to incorporate expert opinion on long-term
HAQ progression where existing data is
insufficient. Mixture models have been fitted
to registry data showing distinct
sub-populations with different HAQ
trajectories. By averaging over these
trajectories, a more realistic non-linear model
could be developed for HAQ progression over
time.
It is important to record the reason for
treatment switching, as this can influence the
choice and efficacy of subsequent treatment.
However, there is an interaction between these
factors, since adverse events are more likely to
lead to treatment being withdrawn if efficacy is
diminished. Estimates of rebound on treatment
termination should be based on data and
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assumptions avoided as far as possible.
However, observations rarely coincide with
treatment switching decisions. Expert
elicitation may be necessary to determine the
most appropriate assumption. While rebound
may in fact occur over a period of time, a step
change is an acceptable simplifying
assumption. Rebound effects are likely to differ
between RA and PsA patients, and data on the
former should not be used as a basis for
estimating rebound in the latter.
Current Available Evidence and Further
Research Needs
Estimating Duration of Treatment in
Responders Existing models use diverse data
sources for estimates of biologic treatment
duration, and interpret those data in different
ways. None of these approaches were thought
to satisfy the requirements of the consensus
model, and further research is required to
establish treatment duration distributions
based on up-to-date and relevant data.
Registries have several advantages as the basis
for estimating this information—they are often
comprehensive, provide detailed patient-level
data, and are up-to-date. Registries could also be
used to explore the impact of effect
modification and the extent to which
treatment duration differs between biologics,
although as a non-randomized data source such
analyses should be interpreted with caution.
Disease Progression on Long-Term
Treatment The consensus group also felt
existing modeling approaches to disease
progression were not appropriate for the
consensus model. In particular, the
assumption of linear HAQ progression leads to
patients in the model reaching HAQ ceiling
values earlier than is observed with real
patients. Research is currently underway
exploring non-linear HAQ progression models.
Once this research is fully available it may prove
an appropriate basis for the consensus
approach. If the data available do not provide
definitive evidence for long-term HAQ
progression, they may be supplemented with
elicitation of expert opinion.
Mappings Between Disease-Specific Severity
Measures and Health-Related QoL Mappings
between HAQ and QoL scores have been
developed using trial and/or observational
data. Mappings currently used in models do
not account for the independent impact of pain
on QoL, and do not draw fully on all currently
available evidence. Further work is required to
produce definitive mapping functions between
HAQ scores (with pain if appropriate) and QoL.
This will first involve identifying the appropriate
data sources, which may include registries and/
or IPD from trials (if available). The appropriate
method for deriving mapping algorithms from
this data will then need to be identified. For PsA,
data collected by the GRACE study may provide
information to map combined joint, skin and
pain symptoms to QoL scores.
Impact of Treatment Switching on
HAQ Empirical estimates of HAQ rebound on
treatment withdrawal are challenging to derive
and lacking in existing literature. Such
estimates could be derived from registry data,
although follow-up visits often do not coincide
with treatment withdrawal, limiting the
accuracy of estimation. Elicitation techniques
could be used to capture clinical judgment on
rebound if empirical approaches are
unsuccessful. Given the challenges of
estimating rebound, the sensitivity of
cost-effectiveness findings to alternative
assumptions should be explored within the
consensus model.
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Estimating Lifetime Costs and Benefits
Summary of Consensus View
• Models should allow for an association
between disease severity and mortality.
• Models should adopt the decision-maker’s
chosen perspective for costs included. This
may involve assuming health care utilization
to be a function of disease severity.
Outcome of Workshop Discussions
There is evidence to suggest disease severity has
an impact on age-adjusted mortality risk, but
not to suggest that choice of treatment has any
additional influence on mortality. For PsA, skin
symptoms may be additionally associated with
mortality. The cost perspective of a model
should reflect the preferences of the
decision-maker involved. In the UK, for
example, the reference case perspective for
NICE technology appraisals is health and
personal social care costs only. An
acceptable approach to modeling the indirect
impact of treatment on such costs is to assume a
relationship between disease severity and
resource use. For PsA, resource use should be
modeled as a function of both joint and skin
symptoms (although double counting should
be avoided). Where models use discrete
time-cycles, cycle duration should be short
enough to accurately reflect resource use
patterns.
Current Available Evidence and Further
Research Needs
Arthritis Health Care Utilization Research is
required to collate diverse evidence on the
relationship between disease severity in RA
and PsA and healthcare utilization. This
research should initially take the form of
identifying current literature and appropriate
data sources. The relationship between disease
severity and health care utilization has been
estimated in several published analyses drawing
on routine data. Work that has informed
existing models includes analysis of registry
data from the US [21] and Sweden [22]. More
recently, analysis has been published of the
total costs for patients with RA and PsA,
including productivity losses, using Norwegian
registry data [23].
Mortality and Disease Severity There are
conflicting findings in the literature regarding
the relationship between mortality and disease
severity. Research is therefore required to
establish a definitive estimate for the
consensus model. Routine data may provide
the most appropriate source for this
relationship. For example, Lunt et al. have
analyzed mortality data in the BSRBR for this
relationship [24], and their analysis included
covariates such as disease duration and severity.
Additional research would identify the full
current evidence base and use this to derive
the consensus relationship, either through
synthesis of multiple evidence sources or
establishing clinical consensus on the most
appropriate data source.
Structural Modeling Approaches
Summary of Consensus View
• Models should be able to represent response
for each biologic therapy in a sequence, but
do not need to model individual
post-biologic conventional DMARDs.
• Individual patient models have several
advantages when representing RA and PsA
patient histories, but the merits of cohort
modeling approaches should also be
explored.
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Outcome of Workshop Discussions
Models should have the flexibility to explore
alternative positions for biologics within the
sequence of treatments. While there may be
benefit in modeling specific DMARD sequences
once biologic therapies have been exhausted,
the group felt that treatments have limited
effects at this stage in practice. Therefore, it is
preferable not to explicitly model sequences of
conventional DMARDs following biologic
therapy, unless data on such patients
becomes available that credibly challenges
this view.
The group noted that both cohort and
individual sampling approaches have been
adopted by previous models, and there were
divergent views over the relative merits of
these approaches. Guidance exists in the
literature on factors which should influence
the choice of model type [25, 26]; as a
general principle, models should be as
simple as possible whilst remaining
consistent with the underlying decision
problem and theory of disease [27].
However, the appropriate model structure
for the evaluation of biologics in arthritis
has not been definitively established in the
literature, and remains a question of both
practical and methodological interest.
Current Available Evidence and Further
Research Needs
Given the alternative approaches to model
structure in existing models, future research
should involve developing models that follow
the consensus approach as closely as possible
whilst adopting alternative structures, to
evaluate how closely each model structure is
able to follow the consensus approach and
the impact of structure on model results.
DISCUSSION
Decision-analytic models have become a key
resource in health technology assessment.
However, models are often developed
independently by manufacturers, academic
groups and regulatory bodies, leading to a
range of models with divergent structures and
conclusions, as is the case for biologic therapies
for inflammatory joint diseases [8]. This can lead
to confusion over the assumptions and data
selection choices driving results, and skepticism
of the validity of model results. Our aim was to
show how a process of bringing together
independent modeling and clinical experts
could lead to clear consensus guidance for
future models, increasing their credibility. It
may not be feasible or desirable to require
manufacturers or academic experts to follow
the consensus approach in every detail. The
former might view this as restricting their ability
to fairly present the benefits of their product, and
the latter might wish to follow their own
academic opinion on the appropriate modeling
approach for a specific policy question.However,
if they were encouraged to set out how their
models differed from the consensus approach,
and present the impact of this deviation on their
results, the resulting transparency would
enhance the credibility of recommendations
derived from those models, and help
decision-makers understand the reasons behind
any differences in findings between models.
One limitation of this consensus is that the
working group consisted solely of UK-based
clinicians, models and regulators. Health
technology assessment clearly has aspects that
are country-specific, and this may mean that
certain elements of our consensus would need
to be adapted to other contexts. However, the
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structures we have followed, and many of our
findings, are relevant internationally. Our work
also provides a case study of a process that can
easily be extended to support decision-making
in other disease areas. The process of developing
consensus, and identifying its current limits,
has the added benefit of highlighting areas
where further research is most needed to
support reimbursement decisions.
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